Key result
Pediatric blood pressure prescription fills rise ~8% between 2017 and 2023, driven by adolescent females.
Why the study?
National estimates for blood pressure-lowering prescription trends among the U.S. pediatric population were lacking.
What are the trends in blood pressure-lowering prescription fills among U.S. youth aged 3-17 years between 2017 and 2023?
Observational (n=1,284,456)
What are the trends in blood pressure-lowering prescription fills among U.S. youth aged 3-17 years between 2017 and 2023?
Effect estimate: AAPC 1.48% (95% CI 0.52-2.45)
Absolute Event Rate: 2.09% vs 1.93%
p-value: p=0.011
Blood pressure-lowering prescription fills have increased among U.S. youth from 2017 to 2023, driven primarily by non-guideline-recommended medications, suggesting off-label use for conditions other than hypertension.
Rising BP-lowering fills in US youth, especially adolescent females, warrant monitoring for off-label use; observational data leave drivers and implications open.
Introduction: There are no national estimates for blood pressure-lowering prescription trends among the U.S. pediatric population. This study describes trends in blood pressure-lowering prescription fills among individuals aged 3-17 years by sex and age group. Methods: Data were obtained from IQVIA's Total Patient Tracker database covering 94% of all outpatient retail prescription fills in the U.S. The key outcome was blood pressure-lowering prescription fills during 2017-2023, utilizing a list of 113 generic medications from 21 drug classes. In addition, a subset of 20 medications recommended in the 2017 American Academy of Pediatrics guideline was examined. Annual population percentage and percentage change compared with 2017 were reported, and average annual percentage change was estimated using Joinpoint regression. Results: <0.001). Prescription fills for guideline-recommended medications either remained stable or declined, with some variation by sex and age group. Conclusions: Results indicate growth in blood pressure-lowering prescription fills, especially among females aged 13-17 years. Increases were driven by medications not included in the 2017 American Academy of Pediatrics guideline, suggesting that blood pressure-lowering medications may be increasingly prescribed for conditions other than pediatric hypertension.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) conducted an observational in Pediatric hypertension / Blood pressure-lowering prescription fills (n=1,284,456). Blood pressure-lowering prescription fills (2023) vs. Blood pressure-lowering prescription fills (2017) was evaluated on Population percentage of blood pressure-lowering prescription fills (AAPC 1.48%, 95% CI 0.52-2.45, p=0.011). Blood pressure-lowering prescription fills among US children and adolescents aged 3-17 years increased from 1.93% in 2017 to 2.09% in 2023, driven by a sharp increase among females aged 13-17 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: